Compare BioSymetrics vs Recursion
Customers evaluate the quality of BioSymetrics's products using the following success metrics.
BioSymetrics is 9 yrs old and is based in United States.
BioSymetrics is a biomedical artificial intelligence (AI) company. It connects disease phenotype and genotype data between humans and model systems, uses machine learning to make predictions, and more. It builds machine-learning technology for biopharmaceutical, precision medicine, diagnostics, and medical discovery companies. It was founded in 2015 and is based in New York, New York.
Recursion is 11 yrs old and is based in United States.
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.
Mogility Capital and Plug and Play Accelerator
Why BioSymetrics beats Recursion
Information not available because Recursion has not claimed their profile.
Work for Recursion? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Recursion?
Claim your profile now.
Why They Buy
News & Analysis
BioSymetrics has not been mentioned in our research.
Recursion has been mentioned in our research 8 times.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
ESP Rankings position vendors based on their resources and execution.
BioSymetrics is a Leader in Single cell analysis platforms
The single cell analysis platforms market is an emerging field that offers solutions for the study of individual cells in various biological systems. This market offers a range of platforms, including microfluidic devices, imaging systems, and sequencing technologies, that enable the isolation, characterization, and analysis of single cells. By using single cell analysis platforms, researchers can gain insights into the heterogeneity of cell populations, understand disease mechanisms at the cellular level, and develop personalized treatments based on individual patient responses. Overall, the single cell analysis platforms market offers an opportunity to advance our understanding of cellular function and disease, and accelerate the development of novel therapeutics.